Next Generation Antibody-Drug Conjugates

Introduction

Antibody–drug conjugates (ADCs) have emerged as a transformative class of targeted cancer therapies by combining the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. Over the past two decades, ADCs have shifted from conceptual innovation to clinical reality, demonstrating substantial therapeutic benefits in multiple hematologic and solid tumor types. Despite early challenges with therapeutic index and off-target toxicities, continued advances in antibody engineering, linker technology, and payload design have expanded the therapeutic potential of ADCs. Recent research has pivoted toward next-generation ADCs that seek to improve selectivity, reduce resistance mechanisms, and engage additional anti-tumor mechanisms beyond direct cytotoxicity.

ADC’s: Concept and Mechanism for Cancer Therapy

Antibody–drug conjugates are comprised of three fundamental components: a monoclonal antibody specific for a tumor-associated antigen, a cytotoxic payload, and a linker that connects the payload to the antibody. The therapeutic rationale is straightforward but technically demanding: the antibody binds selectively to a cell surface antigen that is overexpressed on tumor cells; the antigen–ADC complex is internalized into the cell, typically via receptor-mediated endocytosis; and intracellular processing results in release of the cytotoxic drug, which exerts its lethal effect on key cellular machinery.

Target antigen selection is critical, requiring antigens that are highly expressed on cancer cells relative to normal tissue to maximize therapeutic index. Upon binding, ADCs are internalized and trafficked to lysosomes, where enzymatic or pH-dependent cleavage of the linker liberates the active payload. Payloads are usually highly potent cytotoxic agents, often too toxic for systemic administration alone, such as microtubule inhibitors or DNA-damaging agents, which cause mitotic arrest or apoptosis. The design of the linker dictates the release mechanism: cleavable linkers respond to conditions such as low pH or specific intracellular enzymes, while non-cleavable linkers rely on proteolytic degradation of the antibody to release the drug inside the target cell.

Collectively, these design principles aim to concentrate cytotoxicity within the tumor microenvironment and reduce systemic exposure. However, the complexities of internalization, intracellular processing, bystander killing of adjacent tumor cells, and the stability of the linker-drug underlie both efficacy and toxicity outcomes.

Although ADCs are intended to reduce systemic toxicity, off-target effects and on-target, off-tumor toxicities remain significant limitations. Common adverse events across approved ADCs include myelosuppression, peripheral neuropathy, hepatotoxicity, and infusion reactions. Many toxicities are payload-dependent: microtubule inhibitors frequently cause peripheral neuropathy, while DNA-damaging agents are associated with myelosuppression and gastrointestinal toxicity. Linker instability can further contribute to systemic payload release, increasing toxicity in non-target tissues.

Additional safety concerns include cardiotoxicity, particularly with HER2-directed ADCs, and ocular toxicities such as keratopathy observed with certain tubulin-based payloads. Immunogenic responses to the antibody component may also affect both safety and efficacy.

Together, these challenges underscore the importance of careful patient selection, optimized dosing strategies, and continued development of more selective and better-tolerated ADC design.

FDA Approved ADCs

The first FDA-approved ADC, gemtuzumab ozogamicin, gained accelerated approval in 2000 for acute myeloid leukemia, but it was withdrawn and later reintroduced with revised dosing due to safety concerns. Since then, multiple ADCs have achieved regulatory approval across a range of malignancies. Notable examples include brentuximab vedotin for CD30-positive lymphomas, ado-trastuzumab emtansine for HER2-positive breast cancer, and in recent years, a growing number such as polatuzumab vedotin for diffuse large B-cell lymphoma, enfortumab vedotin for urothelial carcinoma, and sacituzumab govitecan for triple-negative breast cancer.

Each approved ADC reflects evolving design features: optimized linkers for stability in circulation, more potent payloads, and improved antibody specificity. Collectively, approved ADCs have demonstrated meaningful improvements in progression-free survival and overall survival in several settings, validating the targeted cytotoxic approach.

Table 1.  Six FDA-approved antibody-drug conjugates (ADCs) that are molecularly and mechanistically distinct

ADCs in Clinical Trials

Beyond approved agents, the ADC pipeline includes dozens of constructs in various phases of clinical development, addressing both hematologic and solid tumors. These investigational ADCs explore new target antigens, integrate novel payload classes such as DNA cross-linkers or topoisomerase inhibitors, and incorporate engineered antibodies with enhanced internalization properties. Many trials are focused on tumor types with unmet medical needs, such as ovarian, pancreatic, and prostate cancers, where conventional therapies have limited efficacy.

Innovations in linker and payload design are central to this pipeline. Cleavable linkers responsive to tumor-specific proteases or reduced intracellular environments are being investigated to improve selective release. Payloads with distinct mechanisms, including DNA minor groove binders or transcription inhibitors, aim to overcome resistance to traditional microtubule inhibitors. Clinical trial strategies often pair ADCs with immune checkpoint inhibitors or targeted therapies to exploit potential synergy. Early results from several Phase I/II trials have demonstrated promising antitumor activity with manageable safety profiles, supporting continued advancement toward regulatory approval.

Cleavable Linker Design Innovations

Linker chemistry that improves selective drug release and therapeutic index

• Protease-cleavable dipeptide linkers
• Novel cathepsin-specific linkers
• Double lock linkers with monosaccharide shields
• Bio-orthogonal and site-specific linkers
• Advanced stability-balanced linkers

Payload Innovations with Distinct Mechanisms

Beyond classic tubulin inhibitors, exploring new cytotoxic or functional mechanisms

• Topoisomerase I inhibitors
• Pyrrolobenzodiazepine dimers

Innovative Antibody Targets

Antigens beyond “classic” cancer targets, enabling therapy for different cancers

• Integrin β6 (IB6): an ADC in Phase III for non-small cell lung cancer and a broad set of solid tumors.
• B7-H3 (CD276): anti-B7-H3 + topoisomerase I inhibitor in Phase III small cell lung and prostate cancer trials.
• CD25: for Hodgkin’s and non-Hodgkin’s lymphomas; represents a distinct immune-associated antigen.

Next Generation ADCs

Dual-Target / Bispecific ADCs

• Dual-target ADCs and bispecific ADCs are designed to recognize two distinct antigens, either expressed on the same tumor cell or on tumor cells and components of the tumor microenvironment. Bispecific constructs can improve tumor selectivity by requiring simultaneous engagement of two antigens, thereby reducing off-tumor binding and sparing normal tissues that express only one antigen. In addition, bispecific ADCs may facilitate internalization and trafficking, potentially enhancing delivery of the payload.

The bispecific format also enables bridging between tumor cells and immune effector cells or stromal elements, further enhancing therapeutic impact. Examples include bispecific ADCs that target a tumor-specific antigen alongside an antigen associated with tumor vasculature or immune checkpoints, aiming to localize cytotoxic activity while modulating the microenvironment. Early preclinical studies have demonstrated enhanced efficacy in models with heterogeneous antigen expression, and clinical translation is underway for selected constructs.

Dual-Payload ADCs

• Dual-payload ADCs incorporate two distinct cytotoxic drugs within a single construct to leverage complementary mechanisms of action. This strategy aims to enhance tumor cell killing and overcome resistance that may arise when a single payload is ineffective. By combining, for example, a DNA-damaging agent with a microtubule inhibitor, dual-payload ADCs can induce multi-faceted stress on cancer cells.

Designing dual-payload ADCs involves balancing the properties of each payload, including potency, hydrophobicity, and release kinetics. Linker chemistry must enable controlled release of both payloads in the intracellular environment without compromising antibody stability. Preclinical evidence suggests that dual-payload constructs can achieve synergistic cytotoxicity in resistant tumor models, and early clinical candidates are being evaluated for safety and efficacy. This dual-payload approach also raises considerations about toxicity, as each payload may contribute to adverse effects.

Immune-Modulating Payload ADCs

• Traditional ADCs deliver cytotoxic agents that kill tumor cells directly. Next-generation ADCs are exploring payloads that engage the immune system to amplify antitumor responses. Immune-modulating payloads include small molecules that activate innate immune pathways such as toll-like receptors (TLRs), stimulator of interferon genes (STING) agonists, or payloads that modulate the tumor microenvironment to promote immune cell infiltration.

The rationale for immune-modulating ADCs is to combine targeted delivery with local immune activation, potentially converting immunologically “cold” tumors into “hot” ones that are more responsive to immunotherapy. Preclinical models have demonstrated that targeted delivery of immune agonists can induce robust antitumor immunity with reduced systemic cytokine release compared to untargeted systemic administration.

Peptide / Small-Format Conjugates

• While full-length antibodies provide high specificity and favorable half-life, their large size can limit tumor penetration, particularly in solid tumors with dense stroma. Peptide-based and small-format conjugates are being developed to improve tissue penetration and targeting efficiency. These smaller constructs can achieve more uniform distribution within tumors and potentially enhance binding to antigens with restricted accessibility.

Additionally, reduced size may facilitate faster systemic clearance, which can be advantageous for payloads with narrow therapeutic windows. However, smaller formats often exhibit reduced half-life compared to full-length antibodies, which can limit tumor exposure. Strategies to extend half-life, such as fusion to albumin-binding domains or polyethylene glycol (PEG)ylation, are under investigation. Preclinical studies suggest that small-format conjugates maintain potent antitumor activity with improved penetration, supporting their advancement into clinical evaluation.

BBB-Penetrating ADCs

• The blood–brain barrier (BBB) presents a formidable obstacle to systemic delivery of therapeutics for central nervous system tumors and metastases. Next-generation ADCs are being engineered to cross the BBB by engaging transport mechanisms such as receptor-mediated transcytosis. Targets such as transferrin receptor or insulin receptor can facilitate ADC translocation across the BBB when incorporated into the antibody design.

BBB-penetrating ADCs have the potential to deliver cytotoxic or immune-modulating payloads directly to CNS tumors, addressing a critical unmet need in neuro-oncology. Early research has demonstrated the feasibility of this approach in preclinical models, but clinical translation requires careful balancing of BBB engagement with peripheral safety.

Table 2. Next-generation ADC modalities – examples

Conclusion

Antibody–drug conjugates have evolved from conceptual constructs to clinically validated therapies that deliver potent cytotoxic agents with targeted precision. The success of approved ADCs has established this modality as a mainstay in oncology, yet challenges with toxicity, resistance, and limited tumor penetration persist. Next-generation ADCs endeavor to overcome these barriers by innovating in antigen targeting, payload diversity, immune engagement, molecular format, and delivery to sanctuary sites such as the brain. The continued maturation of ADC technology holds promise for more effective, safer, and broadly applicable cancer therapies. As translational research bridges preclinical advances with clinical outcomes, the future of ADCs is poised to expand the therapeutic arsenal against some of the most intractable malignancies.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)

• ADME/Tox
• Molecular Biology
• The Art of Cell Culture
• Exosomes
• Stability Services
• Potency Assay
• Gene Therapy Assays
• Immunotherapy Assays
• Antiviral Therapy Assays
• cGMP
• MLR
• Cell Based Assays
• ELISA
• Flow Cytometry
• Protein
• PCR-qPCR
• Immunoassay
• Radioimmunoassay
• GLP
• Transfection
• Cell Therapy Assays
• Targeted Protein Degradation
• Research to Commercialization